p39 Control Protein  

SDS-PAGE Results of p35 Control Protein. Lane 1: p39 Control Protein Reduced [5.0μg]. Lane 2: p39 Control Protein Reduced [1.0μg]. Lane 3: Opal Prestained Molecular Weight Marker (p/n MB-210-0500). Lane 4: p39 Control Protein Non-Reduced [5.0μg]. Lane 5: p39 Control Protein Non-Reduced [1.0μg]. 4-20% gel, Coomassie stained. Expected MW of p39-MBP ~77.8kDa.

Western Blot of p35 Control Protein. Lane 1: p39 Control Protein (p/n 000-001-C17) Reduced [0.1μg]. Lane 2: p39 Control Protein (p/n 000-001-C17) Reduced [0.2μg]. Lane 3: Opal Prestained Molecular Weight Marker (p/n MB-210-0500). Lane 4: p39 Control Protein (p/n 000-001-C17) Non-Reduced [0.1μg]. Lane 5: p39 Control Protein (p/n 000-001-C17) Non-Reduced [0.2μg]. Primary Antibody: Anti-p39 (p/n 200-401-C17) at 1:1000 overnight at 2-8°C. Secondary Antibody: Goat anti-Rabbit IgG [H&L] HRP (p/n 611-1302) at 1:40,000 for 30mins at RT. Blocking: BlockOut Buffer (MB-073) for 1hr RT. Expected MW: 77.8kDa. Exp: 10sec.

Systems serology profiling with Borrelia-specific antigens reveals patient heterogeneity. The heatmap shows the Z-scored measurements for 12 features, across 16 antigens for both refractory and responsive patients, visualized with joint fluid measurements in the upper half of the heatmap and serum measurements in the lower half of the heatmap. Only antigens detected above background for at least 30% of samples were included for each measurement. Statistical significance was assessed using the Mann-Whitney nonparametric test, with p values then corrected for multiple hypothesis testing via Benjamini-Hochburg, *p < 0.05, **p < 0.01, ***p < 0.001, else not significant. CRASP1 (p/n 000-001-C18), CRASP2 (p/n 000-001-C19), DbpA (p/n 000-001-B98), DbpB (p/n 000-001-C16), Arp37 (p/n 000-001-C09), flagellin (p/n 000-001-C14), OspA (p/n 000-001-C13), OspB (p/n 000-001-C15), OspC (p/n 000-001-C11), OspE (p/n 000-001-C10), p27 (p/n 000-001-C30), p35 (p/n 000-001-C12), p39 (p/n 000-001-C17), VlsE (p/n 000-001-C33). Fig 1. PMID: 38303696.

Antigen-specific IgG2, IgA1, and ADCD partitioning between compartments differs significantly across disease phenotypes. (A) Fraction of samples with non-zero measurements for ADCD, IgG1, IgG2, IgG3, and IgA1 for refractory (dark blue) and responsive (green) patients in the serum (dashed line) and joint fluid (solid line) for each antigen. Significant differences in distribution of non-zero measurements between fluids as assessed by a Fisher’s exact test are denoted as *p < 0.05, **p < 0.01, ***p < 0.001 for refractory (dark blue) and responsive (green) samples after correction for multiple hypothesis testing via Benjamini-Hochburg. (B) Ratio of fraction of serum samples with non-zero measurements to fraction of joint fluid samples with non-zero measurements for ADCD, IgG1, IgG2, IgG3, and IgA1 for refractory (dark blue) and responsive (green) patients for each antigen. Significant differences in distributions of ratios between phenotypes are assessed by a Mann-Whitney nonparametric test, then corrected for multiple hypothesis testing via Benjamini-Hochburg. CRASP1, CRASP2, DbpA, DbpB, Arp37, flagellin, OspA, OspB, OspC, OspE, p27, p35, p39, VlsE: Rockland antigens. Fig 6. PMID: 38303696.